• भारत सरकार के विज्ञान एवम प्रौदयोगिकी मंत्रालय के जैव प्रौदयोगिकी विभाग की स्वायत्त संस्थान
  • AN AUTONOMOUS INSTITUTE OF DEPT. OF BIOTECHNOLOGY, MINISTRY OF SCIENCE AND TECHNOLOGY, GOVT OF INDIA
  • Home
  • Faculty Profile
Publication
  1. Singh RK, Sodhi R, Sharma S, Dastidar SG, Tandon RTargeting MAPAKAP2(MK2) to combat inflammation by avoiding the differential regulation of anti-inflammatory genes by p38 MAPK inhibitors. BioRxiv doi: https://doi.org/10.1101/2022.07.17.500377                July 2022 (*Corresponding author)

  2. Visaga SA,  Kalonia H,  Verma V,  Sinha S,  Singh SK,  Upadhyay S, Sahdev S,  Pansari P,  Kumar R,  Bandgar M, Karanjule N, Shirumalla RK,  Morishita K, Tandon R.Developing selective FPR2 agonists can be a potential approach to treat moderate to severe asthma. J Clin Toxicol, Vol.12 Iss.3 No:1000510, June 2022(*Corresponding author)

  3. Tandon RSoni A., Singh R.K., Sodhi R., Seth MK.,  Sinha S., Dhage G., Das B., Dastidar SG, Shriumalla RK. Marumoto S, Nagayama T. Identification of novel Urotensin-II receptor antagonists with potent inhibition of U-II induced pressor response in mice(2020) Euro J  Pharmacol 886:173391. DOI: 10.1016/j.ejphar.2020.173391, PMID: 32745605 (Corresponding author

  4. Soni A, Agarwal A, Saha S, Shripati KR, Das M, Das B, Cliffe I, Tandon R, Singh RK, Dastidar S, Singh SK, Sinha S, Shriumalla RK, Semwal VP, Marumoto S, Nagayama T. Design, synthesis, and SAR of 2-acetamido-3-pyrrolidinepropanamide derivatives as Urotensin-II receptor antagonists, 250th American Chem Soc.  National Meetings and Expositions, Boston, MA, USA, Aug, 2015

  5.   Tandon R,Senthil V., Nithya D., Venkataramanan R.,  Pamidiboina V., Kumar A, Malik S, Chaira T, Diwan M, Gupta P, Venkataramanan R, Malik R, Das B, Dastidar SG, Cliffe IA; Ray A; Bhatnagar PK. RBx10080307, a dual EGFR/IGF-1R inhibitor for anticancer therapy(2013) Euro J  Pharmacol 711(1-3):19-26.DOI: 10.1016/j.ejphar.2013.04.016PMID: 23639757  (Corresponding author)

  6. Singh RK, Tandon R, Dastidar SG, Ray A. A review on leukotrienes and their receptors with reference to asthma (2013) J Asthma 50(9):922-931.  DOI: 10.3109/02770903.2013.823447PMID: 23859232 

  7. Tandon R,Kapoor S, Vali S, Senthil V., Nithya D., Venkataramanan R, Sharma A, Talwadkar A, Ray A, Bhatnagar PK and Dastidar SG. Dual epidermal growth factor receptor (EGFR)/insulin-like growth factor-1 receptor (IGF-1R) inhibitor: A novel approach for overcoming resistance in anticancer treatment (2011) Euro  J Pharmacol 667(1-3):5665.DOI: 10.1016/j.ejphar.2011.04.066  PMID: 21640718  (Corresponding author)

  8. Tiwari P, Saini S,  Upmanyu S, Benjamin B,  Tandon R, Saini KS and Sahdev S. Enhanced expression of recombinant proteins utilizing a modified baculovirus expression vector.(2010) Mol  Biotechnology 46(1):80-9.  DOI: 10.1007/s12033-010-9284-3PMID: 20424933

  9. Tandon R, Singh MP, Haq W, Dixit M, Patnaik GK and Dhar MM (2010) Design and synthesis of novel tetrapeptides as potential ACE inhibitors.Cheminformatics 28, 40.

  10. Subhadra LB,  Sundaresan S,  Singaravelu A,  Kadapakkam SN,  Badri NR, Katiyar C,  Kanaujia  A, Duggar R, Singh Y,  Konasubrahmanya S,  Bansal V, Sarin S,  Tandon R,  Sharma S and Singh S. (2009) Cinnamic acid isolated from the bark of Cinnamomum cassia regulates glucose transport through activation of glucose transporter 4 on L6 myotubes in a PI3 Kinase independent fashion. J Diabetes 1, 99-106. DOI: 10.1111/j.1753-0407.2009.00022.xPMID: 20929506

  11. Soni A, Agarwal A, Saha S, Das M, Shripati K, Aeron S, Das B, Cliffe I, Tandon R, Singh R, Sodhi R. Design, synthesis, and SAR of 2-acetamido-3-pyrrolidinepropanamide derivatives as urotensin-II receptor antagonists. Abstracts of the papers of the American Chemical Society 2015 Aug 16 (Vol. 250). 1155 16TH ST, NW, Washington, DC 20036 USA: AMER CHEMICAL SOC.

  12. Tandon R, Gupta A, Ray A (2013)  Mechanism of action of antidiabetic property of cinnamic acid, a principal active ingredient from the bark of Cinnamomum cassiaInt J Therap Appls, 9, 2013, 39-45.  (Corresponding author)

  13. Zhang M, Deng Y, Tandon R, Bai C, Riedel H. ( 2008) Essential role of PSM/SH2-B variants in insulin receptor catalytic activation and the resulting cellular responses J Cell Biochem, 1;103(1):162-81. DOI: 10.1002/jcb.21397PMID: 17615553

  14. Sarma PK, Tandon R, Gupta P, Dastidar SG, Ray A, Das B, Cliffe IA(2007) Progress in the  development of small molecule inhibitors of insulin-like growth factor-1 receptor kinase. Exp Opin Ther Pat 17(1) 25-35 (11) https://doi.org/10.1517/13543776.17.1.25

  15. Mittra S, Sangle G, Tandon R, Sharma S, Roy S, Khanna V, Gupta A, Sattigeri J, Sharma L,  Khattar SK, Bora RS, Saini KS, Bansal VS (2007) Increase in weight induced by muraglitazar, a dual PPAR alpha/gamma agonist, in db/db mice: adipogenesis/or oedema? Br J Pharmacol, 150(4):480-7.  DOI: 10.1038/sj.bjp.0707000PMID: 17211457

  16. Deng Y, Bhattacharya S, Swamy OR, Tandon R, Wang Y, Janda R, Riedel H.(2003) Growth factor receptor binding protein 10 (Grb10) as a partner of PI 3kinase in metabolic insulin action. J Biol Chem; 278(41):39311-22.   DOI: 10.1074/jbc.M304599200PMID: 12783867 

  17. Singh SB*, Tandon R*, Krishnamurthy G, Vikram R, Sharma N, Basu SK and Mukhopadhyay A (2003) Rab5-mediated endosome-endosome fusion regulates hemoglobin endocytosis in Leishmania donovani. EMBO J; 22(21) :5712-22.   DOI: 10.1093/emboj/cdg557PMID: 14592970 (Co-first author*)

  18. Narayan P, Pandey R, Yadav VS, Tandon R, Haq W, Dhar MM , Singh VK (2003). Inhibition of anti-CD3 and interleukin-2 stimulated T lymphocyte proliferation by peptidomimetic opioid compound. Immunopharmacol Immmunotox ;25(2):225-33. DOI: 10.1081/iph-120020472  PMID: 12784915

  19. Narayan P, Tandon R, Haq W, Dhar and MM Singh VK (2002) Inhibition of antigen specific lymphocyte proliferation and cytokine stimulation by peptidomimetic opioid compound. Int Immunopharmacol 2 :751-757. DOI: 10.1016/s1567-5769(02)00011-5PMID: 12095165

  20. Narayan P, Singh VK, Agarwal SS, Tandon R, Haq W, Raghubir R and Dhar MM (2001) Immunomodulation by Opioid Peptidomimetic Compound. Neuroimmunomodulation 9:134-40.   doi: 10.1159/000049017. PMID: 11752886

  21. Sengupta S, Tripathi J, Tandon R, Roy RP, Basu SK and Mukhopadhyay A (1999) Hemoglobin endocytosis in Leishmania is mediated through a 46 kD protein located in flagellar pocket. J Bio Chem  274(5), 2758-2765.  DOI: 10.1074/jbc.274.5.2758PMID: 9915807

  22. Tandon R, Singh MP, Haq W, Dikshit' M, Patnaik  GK, Dhar MM (1997), Synthesis of novel tetrapeptides as potential ACE inhibitors. I J Chem, 36B.

  23. Yousaf N, Deng Y, Tandon R, Cheng DW, Kang Y and Riedel H  (2001). Mus musculus Pro-rich, PH and SH2 domain-containing signaling mediator alpha mRNA, complete cds, alternatively spliced. NCBI GenBank; Accession number AF421138.

  24. Yousaf  N, Deng Y, Tandon R, Cheng DW, Kang Y and Riedel H (2001). Mus musculus Pro-rich, PH and SH2 domain-containing signaling mediator gamma mRNA, complete cds, alternatively spliced. NCBI GenBank Accession number AF421139.

  25. Yousaf N, Deng Y, Tandon R, Cheng DW, Kang Y and Riedel H(2001). Mus musculus PSM/SH2-B delta (Sh2B psm1) mRNA, complete cds. NCBI GenBank Accession number AF380422.   

1. Team including Tandon R, Chauthaiwale V et al Heat shock protein inducers in myocardial and cerebral ischemia. (2004) Torrent pharmaceuticals ltd.           Gujarat, India, Pct File No. Pct/in05/00112, Patent File No. 178/kol/2004

2. Team including Tandon R, Dhar MM et al ."An improved process for the preparation of polypeptide useful as Gonadotropin Releasing Hormone agonist       having C-Terminal Proline ethylamide". Patent application No. 3069/DEL/97

  • CSIR, New Delhi, India Award  1997
  • International Travel award, National Research Center for Biotechnology, Braunschweig, Germany, 1999
  • Postdoctoral Research Associate, Wayne State University, MI, USA (National Institute of Health, Bethesda, USA Fellowship) 2000
  • Individual Excellence Award, Ranbaxy Research Labs, 2006 
  • Assistant Director position, Daiichi Sankyo Pharma, 2010
  • Star Team award, Daiichi Sankyo, 2012 
  • SMART Team award, Daiichi Sankyo, 2013 
  • Assistant Director and Group Head, Pharmacology, Daiichi Sankyo Pharma, 2014
  • Served as an active reviewer of articles submitted to international peer reviewed journals such as PLOS One, Oncology Rev and Frontiers in Pharmacology
  • Member, Editorial Board, Frontiers in Pharmacology

NCBI Nucleotide Accessions 

1- Yousaf N, Deng Y, Tandon R, Cheng DW, Kang Y and Riedel H (2001) Mus musculus Pro-rich, PH and SH2 domain containing signaling mediator alpha mRNA, complete     cds, alternatively spliced. NCBI GenBank accession number AF421138, GI: 16226080 

2- Yousaf N, DengY, Tandon R, Cheng DW, KangY and Riedel H (2001) Mus musculus Pro-rich, PH and SH2 domain containing signaling mediator gamma mRNA, complete       cds, alternatively spliced. NCBI GenBank accession number AF421139, GI 16226077

3- Yousaf N, Deng Y, Tandon R, Cheng DW, Kang Y and Riedel H(2001) Mus musculus PSM/SH2-B delta (Sh2B psm1) mRNA, complete cds. NCBI GenBank accession   number  AF380422, GI: 15787982

  • 01292876492
  • RUCHI[DOT]TANDON[AT]THSTI[DOT]RES[DOT]IN